- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03298399
Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease
A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, phase I, open label dose escalation study designed to determine the safety and tolerability of autologous, bone marrow-derived MSCs (EPIC2016-MSC003) in patients with SCD undergoing haploidentical HCT.
Study participants are assigned to one of three MSC dose levels: four infusions of MSCs given once per week, four infusions given twice per week, or six infusions given twice per week. Bone marrow (1-2 ml/kg, max 60 ml) will be collected from study participants for autologous MSC expansion a minimum of 28 days prior to first planned MSC infusion. MSCs will be expanded ex vivo in human platelet lysate to the specified dose level. All MSC infusions will be dosed at 2 x 10^6 MSCs/kg recipient weight, with first infusion given on day 0 (day of haploidentical HCT) or day +1. This phase I trial will enroll 12-18 patients with severe SCD undergoing haploidentical HCT, with subjects followed for 1 year following HCT (and MSC infusions).
Prior to MSC infusions, study participants will undergo transplant conditioning and GVHD prophylaxis as follows:
Day -100 to -10: Hydroxyurea 30 mg/kg PO Qday
Day -9: Rabbit anti-thymocyte globulin (ATG) 0.5 mg/kg IV
Day -8: Rabbit ATG 2 mg/kg IV
Day -7: Rabbit ATG 2 mg/kg IV; Thiotepa 10 mg/kg IV
Day -6: Fludarabine 30 mg/m2 IV; Cyclophosphamide 14.5 mg/kg IV
Day -5: Fludarabine 30 mg/m2 IV; Cyclophosphamide 14.5 mg/kg IV
Day -4: Fludarabine 30 mg/m2 IV
Day -3: Fludarabine 30 mg/m2 IV
Day -2: Fludarabine 30 mg/m2 IV
Day -1: Total body irradiation (TBI) 200 centigray (cGy)
Day 0: Haploidentical bone marrow stem cell infusion
Day +3: Cyclophosphamide 50 mg/kg IV
Day +4: Cyclophosphamide 50 mg/kg IV
Day +5: Sirolimus (through day +365); mycophenolate mofetil (MMF) 15 mg/kg/dose three times per day (TID) (through day +35)
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must weigh >25 kg at the time of study entry.
- Must have undergone puberty at the time of study entry to allow pre-transplant fertility preservation to occur, if desired. Puberty will be defined as Tanner III or more in male patients (typically age ≥ 13 years) and menarche in female patients.
Have severe sickle cell disease (SCD) defined as 1 or more of the following:
- Clinically significant neurologic event (stroke) or any neurological deficit lasting > 24 hours;
- History of ≥2 episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea);
- History of ≥3 severe pain crises per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea);
- Administration of regular red blood cell (RBC) transfusion therapy, defined as receiving ≥8 transfusions per year for ≥1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome);
- An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥2.7 m/sec in adult patients.
Have adequate physical function as measured by:
- Lansky or Karnofsky performance score ≥60
- Cardiac function: left ventricular ejection fraction (LVEF) >40% or LV shortening fraction > 26% by cardiac echocardiogram or by multigated acquisition (MUGA) scan.
- Pulmonary function: pulse oximetry with a baseline O2 saturation of ≥90% and DLCO >40% (corrected for hemoglobin)
- Renal function: serum creatinine ≤1.5 x the upper limit of normal for age as per local laboratory and 24 hour urine creatinine clearance >70 mL/min/1.73 m2 or glomerular filtration rate (GFR) >70 mL/min/1.73 m2 by radionuclide GFR.
- Hepatic function: serum conjugated (direct) bilirubin <2x upper limit of normal for age as per local laboratory and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5x upper limit of normal as per local laboratory. Patients with hyperbilirubinemia as a consequence of hyperhemolysis or who experience a sudden, profound change in the serum hemoglobin after a RBC transfusion are not excluded.
- In patients who have received chronic transfusion therapy for ≥1 year and who have clinical evidence of iron overload by serum ferritin or MRI, evaluation by liver biopsy is required. Histological examination of the liver must document the absence of cirrhosis, bridging fibrosis and active hepatitis. The absence of bridging fibrosis will be determined using the histological grading and staging scale as described by Ishak and colleagues (1995).
- Must be HLA typed at high resolution using DNA based typing at HLA-A, -B, -C and DRB1 and have an available related haploidentical bone marrow donor with 2, 3, or 4 (out of 8) HLA-mismatches. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch.
Exclusion Criteria:
- Availability of an 8 of 8 (HLA-A, B, C and DRB1) human leukocyte antigen (HLA) matched sibling or matched unrelated donor
- Presence of donor directed HLA antibodies.
- Severe pulmonary disease (despite above oxygen saturation and DLCO) including severe and uncontrolled asthma (per 2007 NHLBI Guidelines for the Diagnosis and Treatment of Asthma Expert Panel Report 3; http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report), chronic obstructive pulmonary disease, and/or pulmonary hypertension (PH). A diagnosis of pulmonary hypertension (PH) will be made by finding of mean pulmonary artery pressure (mPAP) <25 mm Hg on right heart catheterization. In patients unable and/or unwilling to undergo cardiac catheterization, patients will be excluded with the following constellation of findings based upon presumptive diagnosis of PH (PPV of 62%): TRJ velocity >2.5 m/sec AND either N-terminal pro-brain natriuretic peptide (NT-pro-BNP) ≥160 pg/ml OR 6-minute walk distance <333 m.
- Uncontrolled bacterial, viral or fungal infection in the 6 week before enrollment
- Seropositivity for human immunodeficiency virus (HIV)
- Previous hematopoietic cell transplantation (HCT)
- Participation in a clinical trial in which the patient received an investigational drug or device or the off-label use of a drug or device within 3 months of enrollment
- Demonstrated lack of compliance with prior medical care
- Unwilling to use approved contraception for at least 6 months following transplant
- Pregnant or breastfeeding females
- Allergy to any component of mesenchymal stromal cell (MSC) suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MSC dose level 1
The first three subjects (minimum) will receive four weekly infusions of MSCs.
|
Participants at dose level 1 receive four infusions of MSCs, given once per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
Participants at dose level 2 receive four infusions of MSCs, given twice per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
Participants at dose level 3 receive six infusions of MSCs, given twice per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
|
EXPERIMENTAL: MSC dose level 2
If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
|
Participants at dose level 1 receive four infusions of MSCs, given once per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
Participants at dose level 2 receive four infusions of MSCs, given twice per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
Participants at dose level 3 receive six infusions of MSCs, given twice per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
|
EXPERIMENTAL: MSC dose level 3
If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
|
Participants at dose level 1 receive four infusions of MSCs, given once per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
Participants at dose level 2 receive four infusions of MSCs, given twice per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
Participants at dose level 3 receive six infusions of MSCs, given twice per week.
The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant.
The total number of cells delivered to each patient will depend on their weight and assigned dose level.
The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion.
The infusion can be administered to patients in the inpatient or outpatient setting.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of EPIC2016-MSC003 based upon dose limiting toxicities (DLTs)
Time Frame: 30 days after last MSC infusion
|
DLTs will be defined as any grade ≥3 adverse reaction that is unexpected or considered attributable to the MSC infusion (attribution listed as at least probable).
Because of the medical complexity of subjects on this trial and the lack of described DLTs to MSC infusion, all reported DLTs will be reviewed by the Data and Safety Monitoring Committee (DSMC).
|
30 days after last MSC infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary graft rejection
Time Frame: 42 days after HCT
|
Defined as the absence of donor cells assessed by peripheral blood chimerism assays on day 42.
|
42 days after HCT
|
Late graft rejection
Time Frame: One year after HCT
|
Defined as the absence of donor hematopoietic cells in peripheral blood beyond day 42 in a patient who had initial evidence of hematopoietic recovery with > 20% donor cells.
|
One year after HCT
|
Time to neutrophil engraftment
Time Frame: Up to one year after HCT
|
Defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count of 500/µL after conditioning.
|
Up to one year after HCT
|
Time to platelet engraftment
Time Frame: Up to one year after HCT
|
Defined as the first day of a minimum of 3 measurements on different days that the patient has achieved a platelet count > 50,000/µL AND did not receive a platelet transfusion in the previous 7 days.
|
Up to one year after HCT
|
Lineage specific donor chimerism
Time Frame: Up to one year after HCT
|
Genomic deoxyribonucleic acid (DNA) extracted from peripheral blood will be analyzed for variable number of tandem repeats (VNTR) to detect donor engraftment in myeloid and lymphoid fractions.
|
Up to one year after HCT
|
Immune reconstitution
Time Frame: Up to one year after HCT
|
Immune reconstitution will be assessed post-transplant by standard clinical testing and research testing.
|
Up to one year after HCT
|
Acute GVHD
Time Frame: One year after HCT
|
Incidence of grade II-IV and III-IV acute GVHD
|
One year after HCT
|
Chronic GVHD
Time Frame: One year after HCT
|
Incidence and severity of chronic GVHD
|
One year after HCT
|
Transplant-related mortality (TRM)
Time Frame: One year after HCT
|
Defined as any death occurring in continuous complete remission
|
One year after HCT
|
Event-free survival (EFS)
Time Frame: One year after HCT
|
Defined as survival with stable donor erythropoiesis and no new clinical evidence SCD.
Primary or late graft rejection with disease recurrence or death will count as events for this endpoint.
|
One year after HCT
|
Overall survival (OS)
Time Frame: One year after HCT
|
Defined as survival with or without SCD after HCT
|
One year after HCT
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth Stenger, MD, Emory University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00090514
- 1K23HL133446 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Autologous MSCs
-
Arda KianiRoyan InstituteUnknownEmphysemaIran, Islamic Republic of
-
Hospital e Maternidade Dr. Christóvão da GamaIEP São Lucas - Instituto de Ensino e Pesquisa; Clinica Jordy Sinapse; TECHLIFE...CompletedMotor Neuron DiseaseBrazil
-
Emory UniversityCURE FoundationCompletedAcute Graft Versus Host Disease | Chronic Graft Versus Host Disease | Graft Versus Host DiseaseUnited States
-
R-BioAsan Medical CenterCompletedRomberg's Disease | Progressive Hemifacial AtrophyKorea, Republic of
-
R-BioKorea University Anam HospitalCompletedSpinal Cord InjuryKorea, Republic of
-
R-BioKorea University Anam HospitalWithdrawnLumbar Intervertebral Disc DegenerationKorea, Republic of
-
R-BioPusan National University HospitalCompletedCritical Limb IschemiaKorea, Republic of
-
R-BioSMG-SNU Boramae Medical CenterCompletedAvascular Necrosis of the Femoral HeadKorea, Republic of
-
Seoul National University HospitalCompletedRotator Cuff DiseaseKorea, Republic of
-
R-BioNot yet recruitingKnee Arthritis | Degenerative ArthritisKorea, Republic of